MedTrace Logo

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

NCT04291885 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2026-04-09

No results posted yet for this study

Summary

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

Conditions

Interventions

DRUG

Avelumab

Avelumab IV infusion

DRUG

Placebo

Placebo IV infusion

Sponsors & Collaborators

  • Melanoma and Skin Cancer Trials Limited

    lead OTHER

Principal Investigators

  • A/Prof Wen Xu, MBBS, FRACP · Princess Alexandra Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2027-04-01
Completion
2030-04-30

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04291885 on ClinicalTrials.gov